In a neoadjuvant study by Baselga et al., treatment with letrozole and everolimus (mTOR inhibitor), a more pronounced reduction in tumor cell proliferation and improved clinical response was observed when compared with letrozole alone in patients with early-stage ER+ BC (270). The gene discussed is ESR1; the disease is breast cancer.